SiBionics and PharmaSens Explore New Horizons for Automated Insulin Delivery
SiBionics presented technology at EASD 2026 that links continuous glucose monitoring with future diabetes care.
SiBionics, a company focused on diabetes care, has presented technology at the European Association for the Study of Diabetes (EASD) conference in Milan that links continuous glucose monitoring with the future of automated insulin delivery.
The company's presented solution, "See More, Act Earlier," aims to improve the quality of life for individuals with diabetes by enabling earlier and more proactive treatment. This technology connects glucose monitoring devices with insulin pump systems, potentially paving the way for automated care.
SiBionics is not alone in pursuing advancements in this field. The exploration with PharmaSens suggests the company is actively seeking partners to develop and expand its technology. Such integrated technologies are crucial developments in diabetes management, aiming to reduce the burden of disease and improve patient outcomes.
Diabetes remains a significant global health challenge, and increased automation in treatment processes could offer substantial benefits. SiBionics' presentation at the EASD conference highlights the rapid progress and new opportunities in leveraging integrated technological solutions for diabetes management.